FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2512098582> ?p ?o ?g. }

• W2512098582 endingPage "98" @default.
• W2512098582 startingPage "89" @default.
• W2512098582 abstract "The prognostic significance of baseline contrast enhancing tumor prior to second- or third-line therapy in recurrent glioblastoma (GBM) for overall survival (OS) remains controversial, particularly in the context of repeated surgical resection and/or use of anti-angiogenic therapy. In the current study, we examined recurrent GBM patients from both single and multicenter clinical trials to test whether baseline enhancing tumor volume, including central necrosis, is a significant prognostic factor for OS in recurrent GBM. Included were 497 patients with recurrent GBM from 4 data sources: 2 single-center sites (University of Toronto, University of California Los Angeles) and 2 phase II multicenter trials (AVF3708G, Bevacizumab ± Irinotecan, NCT00345163; XL184-201, Cabozantinib, NCT00704288). T1 subtraction maps were used to define volume of contrast enhancing tumor, including central necrosis. Cox multivariable and univariate analyses were used to evaluate the relationship between tumor volume prior to second- or third-line therapy and OS. Both continuous measures of baseline tumor volume and tumors dichotomized into large (≥15cc) and small (<15cc) tumors were significant predictors of OS (P<.0001), independently of age and treatment. Univariate analysis demonstrated significant OS differences (P<.05) between large (≥15cc) and small (<15cc) tumors in patients under all therapeutic scenarios. Only patients treated with cabozantinib who previously failed anti-angiogenic therapy did not show an OS dependence on baseline tumor volume. Baseline tumor volume is a significant prognostic factor in recurrent GBM. Clinical trial treatment arms must have a balanced distribution of tumor size, and tumor size should be considered when interpreting therapeutic efficacy." @default.
• W2512098582 created "2016-09-16" @default.
• W2512098582 creator A5006549117 @default.
• W2512098582 creator A5011713808 @default.
• W2512098582 creator A5021656597 @default.
• W2512098582 creator A5025331599 @default.
• W2512098582 creator A5025351354 @default.
• W2512098582 creator A5025556377 @default.
• W2512098582 creator A5038569402 @default.
• W2512098582 creator A5040201315 @default.
• W2512098582 creator A5046758575 @default.
• W2512098582 creator A5050992572 @default.
• W2512098582 creator A5060591628 @default.
• W2512098582 creator A5063511816 @default.
• W2512098582 creator A5064163173 @default.
• W2512098582 creator A5070847041 @default.
• W2512098582 creator A5084965180 @default.
• W2512098582 creator A5087816809 @default.
• W2512098582 date "2016-08-31" @default.
• W2512098582 modified "2023-10-14" @default.
• W2512098582 title "Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials" @default.
• W2512098582 cites W1482109403 @default.
• W2512098582 cites W1510488809 @default.
• W2512098582 cites W1523980033 @default.
• W2512098582 cites W1587922612 @default.
• W2512098582 cites W1624957772 @default.
• W2512098582 cites W1887747927 @default.
• W2512098582 cites W1968841854 @default.
• W2512098582 cites W2011946822 @default.
• W2512098582 cites W2057966391 @default.
• W2512098582 cites W2060619590 @default.
• W2512098582 cites W2062053619 @default.
• W2512098582 cites W2064214863 @default.
• W2512098582 cites W2125372543 @default.
• W2512098582 cites W2140704845 @default.
• W2512098582 cites W2141570482 @default.
• W2512098582 cites W2146933354 @default.
• W2512098582 cites W2150311952 @default.
• W2512098582 cites W2157101750 @default.
• W2512098582 cites W2161648951 @default.
• W2512098582 cites W2266410811 @default.
• W2512098582 cites W2272888082 @default.
• W2512098582 cites W2325421340 @default.
• W2512098582 cites W2434518750 @default.
• W2512098582 cites W2921741526 @default.
• W2512098582 doi "https://doi.org/10.1093/neuonc/now187" @default.
• W2512098582 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5193027" @default.
• W2512098582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27580889" @default.
• W2512098582 hasPublicationYear "2016" @default.
• W2512098582 type Work @default.
• W2512098582 sameAs 2512098582 @default.
• W2512098582 citedByCount "59" @default.
• W2512098582 countsByYear W25120985822016 @default.
• W2512098582 countsByYear W25120985822017 @default.
• W2512098582 countsByYear W25120985822018 @default.
• W2512098582 countsByYear W25120985822019 @default.
• W2512098582 countsByYear W25120985822020 @default.
• W2512098582 countsByYear W25120985822021 @default.
• W2512098582 countsByYear W25120985822022 @default.
• W2512098582 countsByYear W25120985822023 @default.
• W2512098582 crossrefType "journal-article" @default.
• W2512098582 hasAuthorship W2512098582A5006549117 @default.
• W2512098582 hasAuthorship W2512098582A5011713808 @default.
• W2512098582 hasAuthorship W2512098582A5021656597 @default.
• W2512098582 hasAuthorship W2512098582A5025331599 @default.
• W2512098582 hasAuthorship W2512098582A5025351354 @default.
• W2512098582 hasAuthorship W2512098582A5025556377 @default.
• W2512098582 hasAuthorship W2512098582A5038569402 @default.
• W2512098582 hasAuthorship W2512098582A5040201315 @default.
• W2512098582 hasAuthorship W2512098582A5046758575 @default.
• W2512098582 hasAuthorship W2512098582A5050992572 @default.
• W2512098582 hasAuthorship W2512098582A5060591628 @default.
• W2512098582 hasAuthorship W2512098582A5063511816 @default.
• W2512098582 hasAuthorship W2512098582A5064163173 @default.
• W2512098582 hasAuthorship W2512098582A5070847041 @default.
• W2512098582 hasAuthorship W2512098582A5084965180 @default.
• W2512098582 hasAuthorship W2512098582A5087816809 @default.
• W2512098582 hasBestOaLocation W25120985821 @default.
• W2512098582 hasConcept C121608353 @default.
• W2512098582 hasConcept C126322002 @default.
• W2512098582 hasConcept C143998085 @default.
• W2512098582 hasConcept C144301174 @default.
• W2512098582 hasConcept C151730666 @default.
• W2512098582 hasConcept C2776194525 @default.
• W2512098582 hasConcept C2776694085 @default.
• W2512098582 hasConcept C2777802072 @default.
• W2512098582 hasConcept C2779343474 @default.
• W2512098582 hasConcept C2781064419 @default.
• W2512098582 hasConcept C38180746 @default.
• W2512098582 hasConcept C502942594 @default.
• W2512098582 hasConcept C535046627 @default.
• W2512098582 hasConcept C71924100 @default.
• W2512098582 hasConcept C86803240 @default.
• W2512098582 hasConceptScore W2512098582C121608353 @default.
• W2512098582 hasConceptScore W2512098582C126322002 @default.
• W2512098582 hasConceptScore W2512098582C143998085 @default.
• W2512098582 hasConceptScore W2512098582C144301174 @default.
• W2512098582 hasConceptScore W2512098582C151730666 @default.

• next